{"disease":{"id":"stage-iv-esophageal-cancer-ajcc-v7","name":"stage iv esophageal cancer ajcc v7"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03161522","title":"Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01142388","title":"Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":94,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03008278","title":"Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02381561","title":"Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03196232","title":"Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"George Albert Fisher","has_results":true},{"nct_id":"NCT02757391","title":"CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}